HomeProtein ExpressionProstanoid Receptors

Prostanoid Receptors

Prostanoids comprise prostaglandins (PGs) and thromboxanes (Txs). Prostanoid receptors can be classified into five types on the basis of sensitivity to the five naturally-occurring ligands; PGD2, PGE2, PGF2, PGI2 and TxA2. These receptors are termed P receptors, with a preceding letter indicating the natural prostanoid to which each receptor is most sensitive - i.e. DP, EP, FP, IP and TP, respectively. Furthermore, EP receptors have been subdivided into four groups, EP1, EP2, EP3 and EP4, originally on the basis of their relative sensitivities to a range of selective agonists and antagonists, but subsequently, all have been cloned. It is important to appreciate that the recombinant EP4 receptor was originally identified as EP2, and all publications referring to recombinant EP2 receptors prior to 1995 actually refer to EP4 receptors. Evidence for a second subtype of DP receptor has been published, found in T-lymphocytes, and originally termed CRTH2. Interestingly, this receptor is unrelated to the other prostanoid receptors, being more similar to the FPR and BLT chemotactic receptors. Indomethacin acts as an agonist at this receptor, and the TP antagonist, ramatroban, has antagonist activity. This 'new' DP-receptor may now tentatively be termed DP2, with the existing DP receptor re-designated DP1, although this is yet to be made official. Although there is now a substantial body of evidence for subdivision within IP and TP receptors, this has yet to be formally accepted and incorporated within the classification. Isoprostanes, prostanoids synthesized through non-enzymatic conversion of arachidonic acid have been suggested to act at their own receptors, distinct from those for other prostanoids, but the evidence is ambiguous, and the case not proven. In addition, it has been suggested that certain prostaglandins ethanolamides (prostamides) also act at receptors distinct from the ‘classical’ prostanoid receptors, but definitive evidence is still awaited.

The original basis for the classification was functional, and there are many agonists selective for the various prostanoid receptors. However, few agonists are truly selective for one type of receptor over all of the others, exceptions being BW245C at DP (DP1) receptors, fluprostenol at FP receptors, and cicaprost at IP receptors. There are potent antagonists for DP, EP1, EP4 and TP receptors; EP3 antagonists are just emerging, but there are still no well characterized potent selective antagonists at EP2, FP or IP receptors.

Although it is now known that there are splice variants of FP, TP and EPreceptors, they are particularly well established for EP3 receptors, where at least ten splice variants have been reported to date across a variety of species (four of which have been found in man). In all cases, the splicing occurs in the intracellular C-terminal region, and while there is no evidence that it affects ligand affinities, it does appear to influence the receptors’ coupling to particular signal transduction processes. The splice variant of the EP1 receptor is distinct, in that the splice region incorporates the sixth and seventh intracellular domains, and the resulting receptor does not appear to couple directly to any recognized signal transduction process.

Prostanoid-induced effects are mainly transduced through modulation of the activity of either adenylyl cyclase or inositol phospholipid hydrolysis and calcium mobilization. DP1, EP2, EP4 and IP receptors couple positively to adenylyl cyclase through binding to a Gq/11 protein. EP3 receptors can either couple negatively to adenylyl cyclase through binding to a Gi protein, or like EP1, FP and TP receptors, via Gq/11 binding to inositol phospholipid hydrolysis and calcium mobilization. IP receptors appear to be most unusual among the prostanoid receptors, and indeed among G protein-coupled receptors in general, in that the receptor protein requires isoprenylation in order to optimize agonist-induced activation.

The Table below contains accepted modulators and additional information. For a list of additional products, see the "Materials" section below.


a) DP receptor may now be re-designated DP1, with CRTH2 re-designated as DP2.

b) Iloprost is a partial agonist at EP1 receptors, but is a potent full agonist at IP receptors. Sulprostone is more potent as an EP3 agonist.

c) Misoprostol is also an EP3 agonist.

d) Human EP2 receptors only; also antagonist at EP1 and DP receptors.

e) Sulprostone also has moderate EP1 agonistic activity.

f) AH23848 is also a potent TP receptor blocking drug.



AGN 192093: (5Z,9a,11a,13E,15S)-Prosta-5,13-diene-1,9,11,15-tetrol-cyclic-9,11-carbonate
AH-13205: trans-2-(4-(1-Hydroxyhexyl)phenyl)-5-oxocyclopentaneheptanoic acid
AH-23848: [1a(Z),2b,5a]-(±)-7-[5-[[(1,1’-Biphenyl)-4-yl]methoxy]-2-(4-morpholinyl)-3-oxocyclopentyl]-4-heptenoic acid
AH-6809: 6-Isopropoxy-9-oxoxanthene-2-carboxylic acid
Beraprost: (rac-(1R*,2R*,3aS*,8bS*)-2,3,3a,8b-Tetrahydro-2-hydroxy-1-[(E)-(3S*)-3-hydroxy-4-methyl-1-octen-6-ynyl]-1H-cyclopenta[b]benzofuran-5-butyrate)
BM 13505 (Daltroban): 4-(2-(4-Chlorobenzenesulfonylamino)ethyl)benzeneacetic acid
BMS 180291 (Ifetroban): 1S-(1a,2a,3a,4a)]-2-[[3-[4-[(+++Pentylamino)carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]benzenepropanoic acid
BMY 45778: (3-(4,5-Diphenyl(2,4'-bioxazol)-5'-yl)phenoxy)acetic acid
1-BOP: [1S[1a,2a(Z),3b(1E,3S*),4a]]-7-[3-[3-Hydroxy-4-(4-iodophenoxy)-1-butenyl]-7-oxabicyclo- [2.2.1]hept-2-yl]5-heptanoic acid
BW 245C: 3-(3-Cyclohexyl-3-hydroxypropyl)-2,5-dioxoimidazolidine-4-heptanoic acid
BW A868C: 3-Benzyl-5-(6-carboxyhexyl)-1-(2-cyclohexyl-2-hydroxyethylamino)hydantoin
CP-533,536: (3-{[4-Tert-butyl-benzyl(pyridine-3-sulfonyl)-amino-methyl}-phenoxy)-acetic acid
EP092: (1a,2b(Z),3a,4a)-(±)-7-(3-(1-(((Phenylamino)thioxomethyl)hydrazono)ethyl)bicyclo(2.2.1)hept-2-yl)-5-heptenoic acid
GR 32191: (4Z)-7-[(1R,2R,3S,5S)-5-([1,1'-Biphenyl]-4-ylmethoxy)-3-hydroxy-2-(1-piperidinyl)cyclopentyl]-4-heptenoic acid
GR 63799: 7-(3-Hydroxy-2-(2-hydroxy-3-phenoxypropoxy)-5-oxocyclopentyl)-,4-(benzoylamino)phenyl ester,(1R-(1a(Z),2b(R*),3a))-4-heptenoic acid
GW 627368: (N-{2-[4-(4,9-Diethoxy-1-oxo-1,3-dihydro-2H-benzo[f]isoindol-2-yl)phenyl]-acetyl}benzenesulphonamide)
ICI 192605: (4Z)-rel-6-[(2R,4R,5S)-2-(2-Chlorophenyl)-4-(2-hydroxyphenyl)-1,3-dioxan-5-yl]-4-hexenoic acid
KW-3635: Sodium (E)-11-[2-(5,6-dimethyl-1-benzimidazolyl)ethylidene]-6,11-dihydrodibenz[b,e]oxepin-2-carboxylate monohydrate
L-161,982: [4’-[3-Butyl-5-oxo-1-(2-trifluoromethyl-phenyl)-1,5-dihydro-[1,2,4]triazol-4-ylmethyl]-biphenyl-2-sulfonic acid (3-methyl-thiophene-2-carbonyl)-amide]
L-644,698: ±(4-(3-(3-Hydroxyoctyl)-4-oxo-2-thiozolidinyl)propyl) benzoic acid
L-655,240: 3-(1-(4-Chlorobenzyl)-5-fluoro-3-methylindol-2-yl)-2,2-dimethylpropanoic acid
L-798,106: 5-Bromo-2-methoxy-N-[3-2-(naphthalen-2-yl-methylphenyl)-acryloyl]-benzenesulphonamide
ONO-1301: [7,8-dihydro-5-[(E)-[[a-(3-pyridyl)benzylidene]-aminooxy]ethyl]-1-naphtyloxy]acetic acid
ONO-3708: (1S-(1-a,2-b(Z),3-a(S*),5-a))-7-(3-((Cyclopentylhydroxyacetyl)amino)-6,6-dimethylbicyclo(3.1.1)hept-2-yl)-5-heptenoic acid
ONO-AE1-259: (16S-9-Deoxy-9β-chloro-15-deoxy-16-hydroxy-17,17-propano-19,20-didehydro PGE-2)
ONO-AE1-329: (16-(3-Methoxymethyl)phenyl-omega-tetranor-3,7-dithia PGE-1)
ONO-AE1-734: Methyl-7-[(1R,2R,3R)-3-hydroxy-2-[(E)-(3S)-3-hydroxy-4-(m-methoxymethylphenyl)-1-butenyl]-5-oxocyclopenthl]-5-thiaheptanoate
ONO-AE3-208: 4-{4-Cyano-2-[2-(-fluoronaphthalen-1-yl)proprionylamino] phenyl}butyric acid
Ramatroban: (+)-(3R)-3-(4-fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazolepropanoic acid
RS 93520: (4Z)-4-[(1R,2R,3S,6R)-2-[(3S)-3-Cyclohexyl-3-hydroxy-1-propynyl]-3-hydroxybicyclo[4.2.0]oct-7-ylidene]butanoic acid
S-5751: ((Z)-7-[(1R,2R,3S,5S)-2-(5-hydroxybenzo[b]thiophen-3-ylcarbonylamino)-10-norpinan-3-yl]hept-5-enoic acid)
SC 19220: 1-Acetyl-2-[8-chloro-10,11-dihydrodibenz(b,f)(1,4)oxazepine-10-carbonyl]hydrazine
SC 46275: Methyl-7-(2b-(6-(1-cyclopentyl-yl)-4R-hydroxy-4-methyl-1E,5E-hexadienyl)-3a-hydroxy-5-oxo-1R,1a-cyclopentyl)-4Z-heptenoate
SC 51809: (8-Chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-[1-oxo-3-(4-pyridinyl)propyl]hydrazide, monohydrochloride)
SQ 26655: 9-alpha,11alpha-epoxy-10a-homo-15S-hydroxy-prosta-5Z,13E-dienoic acid
SQ 27986: 7-(3-(3-Cyclohexyl-3-hydroxy-1-propenyl)-7-oxabicyclo(2.2.1)hept-2-yl)-5-h eptenoic acid
SQ 29548: 7-(3-((2-((Phenylamino)carbonyl)hydrazino)methyl)-7-oxabicyclo(2.2.1)hept-2-yl)-5-heptenoic acid
STA2: (5Z)-7-[(1S,2R,3R,5S)-3-[(1E,3S)-3-Hydroxy-1-octenyl]-6-thiabicyclo[3.1.1]hept-2-yl]-5-heptenoic acid
U-46619: (5Z)-7-[(1R,4S,5S,6R)-6-[(1E,3S)-3-Hydroxy-1-octenyl]-2-oxabicyclo[2.2.1]hept-5-yl]-5-heptenoic acid
ZK 110841: 9-Deoxy-9-chloro-16,17,18,19,20-pentanor-15-cyclohexyl- PGF 2a
ZK 138,357: (5Z)-7-[(2RS,4S,5S)-2-(2-chlorophenyl)-5-[(1E)-(3RS)-3-hydroxy-3-cyclohexyl-1-propenyl]-1,3-dioxolan-4-yl]-5-heptanoic acid



Coleman, R.A., et al., . 2000. Prostanoid receptors., in: The IUPHAR Compendium of Receptor Characterization and Classification, IUPHAR Media, London, UK.. 2nd edition, pp..337-353.
Díez-Dacal B, Pérez-Sala D. 2010. Anti-Inflammatory Prostanoids: Focus on the Interactions between Electrophile Signaling and Resolution of Inflammation. The Scientific World JOURNAL. 10655-675.
Furuyashiki T, Narumiya S. 2011. Stress responses: the contribution of prostaglandin E2 and its receptors. Nat Rev Endocrinol. 7(3):163-175.
Hayes JS, Lawler OA, Walsh M, Kinsella BT. 1999. The Prostacyclin Receptor Is Isoprenylated. J. Biol. Chem.. 274(34):23707-23718.
Hirata M, Hayashi Y, Ushikubi F, Yokota Y, Kageyama R, Nakanishi S, Narumiya S. 1991. Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature. 349(6310):617-620.
Hirata T, Narumiya S. 2012. Prostanoids as Regulators of Innate and Adaptive Immunity.143-174.
Honda T, Tokura Y, Miyachi Y, Kabashima K. 2010. Prostanoid Receptors as Possible Targets for Anti-Allergic Drugs: Recent Advances in Prostanoids on Allergy and Immunology. CDT. 11(12):1605-1613.
Morrow, J.D., et al., . 1994. Free radical-induced generation of isoprostanes in vivo. Evidence for the formation of D-ring and E-ring isoprostanes., J. Biol. Chem., 269 ..4317-4326.
Nagata K, Hirai H. 2003. The second PGD2 receptor CRTH2: structure, properties, and functions in leukocytes. Prostaglandins, Leukotrienes and Essential Fatty Acids. 69(2-3):169-177.
Okuda-Ashitaka E, Sakamoto K, Ezashi T, Miwa K, Ito S, Hayaishi O. 1996. Suppression of Prostaglandin E Receptor Signaling by the Variant Form of EP1Subtype. J. Biol. Chem.. 271(49):31255-31261.
Pierce KL, Bailey TJ, Hoyer PB, Gil DW, Woodward DF, Regan JW. 1997. Cloning of a Carboxyl-terminal Isoform of the Prostanoid FP Receptor. J. Biol. Chem.. 272(2):883-887.
Praticò D, Smyth EM, Violi F, FitzGerald GA. 1996. Local Amplification of Platelet Function by 8-Epi Prostaglandin F2?Is Not Mediated by Thromboxane Receptor Isoforms. J. Biol. Chem.. 271(25):14916-14924.
Regan, J.W., et al., . 1994. Cloning of a novel human prostaglandin receptor with characteristics of the pharmacologically defined EP2 subtype., 46.. Mol. Pharmacol..213-220 .
Schuligoi R, Sturm E, Luschnig P, Konya V, Philipose S, Sedej M, Waldhoer M, Peskar BA, Heinemann A. 2010. CRTH2 and D-Type Prostanoid Receptor Antagonists as Novel Therapeutic Agents for Inflammatory Diseases. Pharmacology. 85(6):372-382.
Ushikubi F, Hirata M, Narumiya S. 1995. Molecular biology of prostanoid receptors; an overview. Journal of Lipid Mediators and Cell Signalling. 12(2-3):343-359.
Wise H, Joncs RL. 1996. Focus on prostacyclin and its novel mimetics. Trends in Pharmacological Sciences. 17(1):17-21.
Woodward DF, Pepperl DJ, Burkey TH, Regan JW. 1995. 6-isopropoxy-9-oxoxanthene-2-carboxylic acid (AH 6809), a human EP2 receptor antagonist. Biochemical Pharmacology. 50(10):1731-1733.
Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?